Mumbai
Tier 1
$42,000 - $85,000
Specialized cellular therapy programs and ICU backup define the upper range.
Cell therapy cost
CAR-T cell therapy cost in India by eligibility and hospital capability
Plan CAR-T therapy with USD ranges for eligible blood cancer patients, including evaluation, cell collection, manufacturing, bridging therapy, admission, ICU backup, and monitoring.
How much does CAR-T cell therapy cost in India?
CAR-T cell therapy in India commonly requires a planning range from about $35,000 to $85,000 or more depending on therapy product, eligibility, manufacturing pathway, hospital city, bridging therapy, admission length, ICU backup, infection risk, and post-infusion monitoring. It is not a routine cancer package and should be considered only after hematology or cellular therapy review.
City-wise cost
USD range by Indian city
These ranges are planning bands. A hospital-backed quote should be requested after reports, diagnosis, and fitness details are reviewed.
City Tier USD range Planning note
Delhi NCR
Tier 1
$40,000 - $82,000
Useful for hematology, transplant, and cellular therapy review.
Gurugram
Tier 1
$42,000 - $85,000
Often selected for premium hematology programs and international coordination.
Bangalore
Tier 1
$39,000 - $78,000
Strong option where cellular therapy and ICU systems are established.
Chennai
Tier 1
$38,000 - $76,000
Can be suitable in selected hematology centers with CAR-T readiness.
Hyderabad
Tier 1
$38,000 - $75,000
Requires confirmation of product, collection, and complication support.
Pune
Major metro
$36,000 - $70,000
Consider only where cellular therapy capability is verified.
Ahmedabad
Major metro
$36,000 - $70,000
Specialist availability and product pathway must be confirmed.
Kolkata
Major metro
$35,000 - $68,000
May be possible only in selected programs with hematology depth.
Indore
Tier 2
$35,000 - $65,000
Usually not a first-choice city unless a proven cellular therapy pathway exists.
Bhopal
Tier 2
$35,000 - $65,000
Consider mainly for pre/post coordination, not complex infusion, unless capability is proven.
Vizag
Tier 2
$35,000 - $66,000
Confirm cellular therapy unit, ICU, infection control, and hematology team before planning.
Tier choice
When Tier 1 or Tier 2 cities may make sense
Tier 1 is usually preferred
CAR-T requires cellular therapy infrastructure, hematology depth, ICU, infection control, blood bank, and rapid complication response.
Tier 2 only with proven pathway
Tier 2 cities should be considered only if the hospital has verified CAR-T capability and emergency systems.
Plan the full episode
Evaluation, bridging, manufacturing, infusion, ICU risk, infection care, and local monitoring all affect total cost.
Included
What the estimate usually covers
Cell therapy product
CAR-T product or manufacturing pathway as quoted by the hospital or program.
Product details must be explicit.
Evaluation and collection
Eligibility review, cell collection planning, and selected pre-infusion steps if bundled.
Ask what is included.
Admission and infusion
Hospital admission, lymphodepletion if quoted, CAR-T infusion, monitoring, and nursing care.
Length of stay can vary.
Specialist oversight
Hematology, cellular therapy, ICU, infection, and transfusion support during the treatment window.
Team depth is essential.
Not included
What patients should confirm separately
Bridging therapy
Chemotherapy, radiation, steroids, or other treatment needed while cells are prepared.
Often separate.
CRS or neurotoxicity care
ICU, medicines, neurology, ventilation, or prolonged monitoring for CAR-T complications.
Major cost risk.
Infection and transfusions
Antibiotics, antifungals, blood products, isolation, and low-count support.
Common in hematology patients.
Extended local stay
Accommodation near the hospital after discharge for monitoring and urgent access.
Plan this carefully.
Cost drivers
Factors that can change the final estimate
Product and manufacturing
Different CAR-T products and manufacturing pathways have different pricing and timelines.
Confirm product name.
Disease status
High disease burden, relapse, prior transplant, or poor counts can increase bridging and admission needs.
Eligibility review is critical.
Complication risk
Cytokine release syndrome, neurotoxicity, infection, and ICU needs can change final cost.
Budget a safety margin.
Hospital capability
Cell therapy accreditation, hematology depth, ICU, blood bank, and infection control matter.
Do not choose by city price alone.
Post-infusion monitoring
Patients may need close city stay, repeated blood tests, and urgent re-admission access.
Travel planning is part of cost.
Reports
Reports needed for a more accurate quote
The report checklist is different for each treatment so every cost page avoids generic duplicated content.
CAR-T reports
CAR-T evaluation needs detailed hematology history and current disease status.
Diagnosis and disease markers
Biopsy, flow cytometry, immunophenotyping, cytogenetics, and molecular reports define eligibility.
Prior treatment history
Chemotherapy lines, transplant, relapse dates, infections, and response history influence suitability.
Current disease burden
PET CT, marrow report, blood counts, LDH, organ function, and symptoms help estimate risk.
Fitness and infection status
Heart, lung, liver, kidney, viral markers, and active infection status affect treatment timing.
Hospital selection
How to compare hospitals beyond the lowest package
Cellular therapy program
Confirm CAR-T experience, product pathway, manufacturing timeline, and eligibility process.
This is non-negotiable.
Complication readiness
Ask about CRS protocol, neurotoxicity checks, ICU, tocilizumab access, and neurology support.
Safety depends on response speed.
Hematology support
Blood bank, infection control, isolation, transfusion support, and transplant-style care should be available.
Needed for low counts.
Post-discharge monitoring
Clarify local stay days, emergency access, blood-test schedule, and return-home clearance.
Do not rush travel.
Patient journey
From first estimate to treatment travel
Eligibility screening
Hematology reviews diagnosis, prior treatment, disease burden, and fitness for CAR-T.
Collection and bridging
Cells may be collected while bridging therapy controls disease during manufacturing.
Infusion admission
Lymphodepletion, CAR-T infusion, fever monitoring, neurological checks, and infection support occur in hospital.
Close post-infusion stay
Patients remain near the hospital for urgent monitoring before returning home.
Recovery planning
Stay, follow-up, and return-home planning
Early monitoring
Fever, low blood pressure, confusion, seizures, infection, and low counts require urgent attention.
Near-hospital stay
Patients should expect to stay close to the treatment center after discharge for monitoring.
Long-term handoff
The home hematologist should receive treatment dates, complications, medicines, blood counts, and follow-up schedule.
Questions
Common questions
Why is CAR-T cell therapy expensive?
CAR-T involves specialized cell processing, hospital admission, hematology oversight, ICU backup, infection support, and close monitoring for serious side effects.
Is CAR-T used for all cancers?
No. It is mainly used for selected blood cancers in specific clinical situations. Eligibility must be reviewed by hematology or a cellular therapy team.
Can CAR-T be done in Tier 2 cities?
Only if a hospital has verified cellular therapy capability, ICU, infection control, blood bank, and experienced hematology support. Most patients should compare selected Tier 1 centers first.
What reports are needed for a CAR-T estimate?
Diagnosis reports, flow cytometry, cytogenetics, prior treatment history, PET CT, marrow reports, blood counts, organ function, and infection status are important.
Does CAR-T cost include ICU care?
Not always. Patients should ask how cytokine release syndrome, neurotoxicity, infection, ICU, and prolonged stay are billed.
What is bridging therapy?
Bridging therapy controls cancer while cells are collected and prepared. It may add cost before CAR-T infusion.
How long should an international patient stay?
Patients should plan for evaluation, collection, manufacturing or waiting time, infusion admission, and close post-discharge monitoring near the hospital.
Can Virello help compare CAR-T programs?
Yes. Virello can help organize reports and compare eligibility process, product pathway, hospital capability, city logistics, and estimate inclusions.